Eubelius has assisted a consortium of new investors in connection with the successful €54 million Series A financing round in ATB Therapeutics SA, a company dedicated to pioneering first-in-class biologics that incorporate novel cell-killing mechanisms, including enzymatic functionalities, within targeted antibodies.
The financing round was co-led by EQT Life Sciences (through the LSP 7 fund) alongside contributions from i.a. V-Bio, VIVES Partners, SFPIM, Wallonie Entreprendre and Sambrinvest.
The Eubelius team advising on this transaction was led by Filip Jenné, Fréderic Van Campe and Charline Verbist.
For more details, please refer to ATB Therapeutics official press release (https://cms.atbtherapeutics.com/_/assets/a597ch45e00kco0c)
